

Indication	Gynae cancer: epithelial uterine, cervical, vulval, vaginal and ovarian. Head and Neck: Salivary / parotid gland cancer Upper GI: Adenocarcinoma of the lower Oesophagus or Type 1 Or 2 Gastro-Oesophageal Junction Cancer. Urology: First or second / subsequent line treatment in advanced or metastatic urothelial cancer for patients with platinum sensitive disease.
Treatment Intent	Palliative: Ovarian, cervical, vulval, vaginal, Epithelial uterine and salivary / parotid gland and urothelial Adjuvant: Epithelial uterine and ovarian Neo-adjuvant: Epithelial uterine, ovarian and lower oesophagus or type 1 or 2 GO junction
Frequency and number of cycles	Repeat every 21 days. Gynae: 6-8 cycles (stop at 6 for palliative treatment), 4-6 cycles for adjuvant treatment of epithelial uterine cancer. Head and Neck / Urology: up to 6 cycles. UGI: 1-2 cycles followed by weekly carboplatin and paclitaxel with radiotherapy (UGI-036).
Monitoring Parameters pre-treatment	• Virology screening: All new patients referred for systemic anti-cancer treatment should be screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion. • EDTA/DTPA should be used to measure GFR prior to cycle 1. C+G may be used to estimate CrCl if there is a delay in obtaining EDTA result. • Monitor U+Es, LFTs and FBC at each cycle. If CrCl falls by >25% repeat EDTA and d/w consultant. • If neuts <1.5 and/or PLT <100 defer treatment by one week. Consider dose reduction on subsequent cycles • Hepatic impairment: ○ Carboplatin: No dose adjustment required. ○ Paclitaxel: If bilirubin < 1.25 x ULN and transaminase < 10 x ULN, dose at full dose. Otherwise consider dose reduction, not recommended in severe hepatic impairment. • Renal impairment: ○ Carboplatin: stop if CrCl < 30ml/min ○ Paclitaxel: no dose reduction necessary. • Infusion-related reactions: ○ Paclitaxel: Patients developing hypersensitivity reactions to paclitaxel may be rechallenged with full dose paclitaxel following prophylactic medication (e.g. famotidine 40mg po given 4 hours prior to treatment plus hydrocortisone 100mg iv and chlorphenamine 10mg iv 30 minutes prior to treatment, then give paclitaxel over 3-6 hours (i.e. starting at over 6 hours and gradually increase rate if possible). ○ Carboplatin: Mild/moderate reactions (grade 1-2): If symptoms resolve after treatment with hydrocortisone and chlorphenamine, the infusion may be restarted at 50% rate for 30 mins, then, if no further reaction, increase to 100% rate. If symptoms do not resolve after treatment with hydrocortisone and chlorphenamine, do not restart the infusion. At consultant's discretion, patients may be rechallenged at a

Protocol No	MULTI-021	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V2	Written by	M. Archer
Supersedes version	V1	Checked by	C. Waters M. Capomir
Date	26.11.2025	Authorising consultant (usually NOG Chair)	C. Thomas

	later date with additional prophylaxis. In the event of further reaction (grade 1-3), stop infusion and consider alternative treatment. Severe (grade 3): Do not restart infusion. Consider alternative treatment. Anaphylaxis (grade 4): Follow anaphylaxis protocol. Discontinue permanently and consider alternative treatment. • Dose Modification: ○ Paclitaxel: Dose reduce Paclitaxel by 20% in the event of $\geq$ grade 2 neuropathy and consider delay until recovery to $\leq$ grade 1. ○ Consider omitting paclitaxel in event of recurrent grade $\geq$ 3 neuropathy OR recurrent or persistent $\geq$ grade 2 neuropathy following a dose reduction. ○ Dose reduction of carboplatin and paclitaxel should be considered if any other grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to $\leq$ grade 1. • Common drug interactions (for comprehensive list refer to BNF/SPC): ○ Paclitaxel: Caution should be exercised when administering paclitaxel concomitantly with medicines known to inhibit either CYP2C8 or CYP3A4 (e.g. ketoconazole, erythromycin, fluoxetine, clopidogrel, cimetidine, ritonavir and nelfinavir); toxicity may be increased. CYP2C8 or CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine) may reduce efficacy. ○ Carboplatin: Caution with other nephrotoxic drugs.
References	KMCC protocol MULTI-021 V1, KMCC protocol URO-029 V2.1 draft.

NB for funding information, refer to CDF and NICE Drugs Funding List

Protocol No	MULTI-021	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V2	Written by	M. Archer
Supersedes version	V1	Checked by	C. Waters M. Capomir
Date	26.11.2025	Authorising consultant (usually NOG Chair)	C. Thomas

Repeat every 21 days

Day	Drug	Dose	Route	Infusion Duration	Administration
1	Give pre-meds 30 minutes prior to paclitaxel				
	Dexamethasone	16mg	IV	Bolus	
	Chlorphenamine	10mg	IV	Slow bolus	Through the side of a fast running Sodium Chloride 0.9% intravenous infusion.
	Ondansetron	<75yrs 16mg ≥75yrs 8mg	IV	15 min	Sodium chloride 0.9% 50ml
	PACLITAXEL	175mg/m²	IV	3 hrs	In 500ml Sodium Chloride 0.9% (if dose <150mg in 250ml Sodium Chloride 0.9%) Use non-PVC bag and non-PVC administration set via in-line 0.22 microns filter. Flush with sodium chloride 0.9%
	CARBOPLATIN Dose = (GFR + 25) x AUC	AUC 5 (dose capped at 790mg on epx system)	IV	30 mins	Glucose 5% 500ml In clinical practice the dose is usually capped at either 700mg OR for a maximum calculated dose of GFR 125ml/min
TTO	Drug	Dose	Route	Directions	
Day 1	Dexamethasone	6mg	PO	OM for 3 days	
	Metoclopramide	10mg	PO	Take 10mg THREE times a day for 3 days then take 10mg up to THREE times a day when required (Maximum of 30mg per day). Do not take for more than 5 days continuously.	

Protocol No	MULTI-021	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.		
Version	V2	Written by		M. Archer
Supersedes version	V1	Checked by		C. Waters M. Capomir
Date	26.11.2025	Authorising consultant (usually NOG Chair)		C. Thomas